APUSApimeds Pharmaceuticals US, Inc.vs its industry peers
A metric-by-metric comparison of Apimeds Pharmaceuticals US, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APUSThis | $3M#16 | — | 0.0x#1 | — | — | -331.7%#14 | — | -5.6%#2 | -11.2%#3 | — | -89.4%#15 | — |
| RMTI | $32M#2 | 263.5x#2 | 0.9x#6 | 0.5x#1 | -31.8%#6 | -1007.1%#15 | -6.8%#1 | -15.1%#4 | -14.0%#4 | 4#3 | -40.8%#8 | — |
| ABVC | $31M#3 | — | 3.0x#9 | 105.4x#7 | 0.0%#3 | -61.3%#12 | -2416.0%#7 | -76.9%#6 | -68.5%#5 | — | -57.1%#10 | — |
| BRNS | $31M#4 | — | 0.5x#2 | — | -100.0%#9 | -8.8%#9 | — | -116.4%#9 | — | — | -37.0%#6 | — |
| CPHI | $31M#5 | — | 0.9x#4 | 7.5x#4 | -8.5%#5 | 32.7%#6 | -78.2%#2 | -8.8%#3 | -7.7%#2 | 5#1 | -63.5%#11 | — |
| KYNB | $31M#6 | 0.2x#1 | — | 4.8x#3 | -78.3%#7 | 485.6%#1 | -712.7%#6 | — | — | — | -37.9%#7 | — |
| RNAZ | $31M#7 | — | — | — | — | -106.9%#13 | — | — | — | — | -83.9%#13 | — |
| NNVC | $31M#8 | — | 3.4x#10 | — | — | -14.1%#10 | — | -103.4%#7 | -89.9%#6 | — | 0.0%#3 | — |
| HEPA | $29M#9 | — | 22.4x#12 | — | — | 37.3%#5 | — | -647.5%#12 | — | — | -17.6%#4 | — |
| IGC | $28M#10 | — | 4.6x#11 | 22.2x#6 | -5.5%#4 | 45.2%#4 | -585.8%#5 | -116.1%#8 | -125.5%#7 | 3#4 | -34.2%#5 | — |
| NXTC | $26M#11 | — | 2.2x#8 | 1.2x#2 | 252.6%#1 | -0.3%#8 | -257.5%#4 | -459.7%#11 | — | — | 0.5%#2 | — |
| TXMD | $25M#12 | — | 0.9x#7 | 8.4x#5 | 71.6%#2 | 73.9%#2 | -145.3%#3 | -2.1%#1 | -3.8%#1 | 5#1 | 93.8%#1 | — |
| ACTU | $24M#13 | — | 24.3x#13 | — | — | 18.5%#7 | — | -2247.2%#13 | — | — | -85.6%#14 | — |
| ATOS | $24M#14 | — | 0.9x#5 | 13623.6x#8 | -95.6%#8 | -36.3%#11 | -2112684.9%#8 | -129.6%#10 | — | — | -80.7%#12 | — |
| LTGO | $1.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| CLRB | $23M#15 | — | 0.8x#3 | — | — | 51.1%#3 | — | -72.9%#5 | — | — | -54.7%#9 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice